|
|
|
Natural and revolutionary tumor-specific T-cell therapy |
| Zhi Dai, Xue-Meng Liu, Yun-li Zhao, Li-Xing Zhao, Xiao-Dong Luo |
| Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, School of Chemical Science and Technology, Yunnan University, Kunming 650500, People's Republic of China |
|
|
|
|
Abstract Recently the FDA conducted a risk investigation and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy? Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC+ cancer cells and Naïve-T cells under the CD28 co-stimulatory signals. These tumor-specific T-cells could be separated through cell size and abundantly produced from peripheral blood, and would spontaneously attack target cells that carrying the same tumor antigen while avoiding others in vitro test. Moreover, it markedly decreased 90% tumor nodules companying with greatly improving overall survival (76 days vs 30 days) after twice infusion back to mice. This work maximally avoided the risks of secondary cancer and non-specific killing, and might open a revolutionary beginning of natural tumor-specific T-cell therapy.
|
| Keywords
Natural T-cell therapy
Specific killing
MHC+ tumor
CD28 signal
Without virus
Safety
|
| Fund:This work was financially supported by the High-level Talent Promotion and Training Project of Kunming (2022SCP003), the Project of Yunnan Characteristic Plant Screening and R&D Service CXO Platform (2022YKZY001), and the Scientific and Technological Innovation Team of Yunnan Province (202105AE160006). |
|
Corresponding Authors:
Zhi Dai,E-mail:daizhi@ynu.edu.cn;Xiao-Dong Luo,E-mail:xdluo@ynu.edu.cn
E-mail: daizhi@ynu.edu.cn;xdluo@ynu.edu.cn
|
|
Issue Date: 13 December 2024
|
|
|
[1] Sarkizova S, Hacohen N. CANCER IMMUNOTHERAPY How T cells spot tumour cells. Nature. 2017;551(7681):444-6.
[2] Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9.
[3] Baker DJ, et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707-15.
[4] Irvine DJ, et al. The future of engineered immune cell therapies. Science. 2022;378(6622):853.
[5] Zhang JQ, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369.
[6] Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635-48.
[7] Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724-40.
[8] Arnaud M, et al. Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat Biotechnol. 2022;40(5):656.
[9] Veatch JR, Simon S, Riddell SR. Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer. Nat Med. 2021;27(8):1339-41.
[10] Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-7.
[11] Netea MG, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375-88.
[12] Barennes P, et al. Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases. Nat Biotechnol. 2021. https://doi.org/10.1038/s41587-020-0656-3.
[13] Lever M et al. Phenotypic models of T cell activation. J Immunol 2015;194.
[14] Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020;20(8):483-97.
[15] Lawson DA, et al. Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol. 2018;20(12):1349-60.
[16] Karakus U, et al. MHC class II proteins mediate cross-species entry of bat influenza viruses. Nature. 2019;567(7746):109.
[17] Shultz LD, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477-89. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
